Pharmaceuticals heavyweight Novartis is changing the name of its previously indirect subsidiary AveXis to Novartis Gene Therapies. The Swiss drugmaker said the change...
11.04.2018
- In an all-cash deal expected to close in the second half of this year, Swiss drugs giant Novartis has agreed to pay $8.7 billion for AveXis, a US-based clinical stage gene therapy...
